Cynapsus Therapeutics Inc Stock

Stocks

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
06-03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
05-20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
24-03-11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
24-01-29	CoTec Holdings Outlines Key Targets For 2024	MT
24-01-03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
23-10-10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
23-10-10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
23-10-02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
23-09-14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
23-09-14	CoTec Holdings, Mkango To Form US Joint Venture	MT
23-06-30	Kings Chapel Increases Stake In CoTec Holdings	MT

05-06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
16-08-31	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
16-08-29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
16-08-15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
16-08-12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	+2.35%	+0.77%	+29.92%	+85.38%	55.23B
ARGENX SE	-0.21%	-7.38%	+25.34%	+63.02%	53.75B
BIONTECH SE	-2.44%	+1.40%	-15.74%	-16.80%	23.48B
INSMED INCORPORATED	-2.85%	-7.78%	-8.09%	+346.36%	22B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-1.27%	+15.99%	-10.53%	19.78B
GENMAB A/S	+0.79%	-2.39%	+26.99%	-31.34%	17.44B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-7.23%	+24.50%	+519.07%	14.66B
EXELIXIS, INC.	-5.25%	-4.23%	+46.41%	+169.05%	14.07B
PHARMAESSENTIA CORPORATION	+3.41%	-7.83%	+161.76%	+284.91%	13.02B
Average	-0.11%	-2.36%	+34.12%	+156.57%	25.94B
Weighted average by Cap.	+0.17%	-0.53%	+27.30%	+121.10%

Employees

Sector